Pancreatic ductal adenocarcinoma: metastatic disease Review uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Pancreatic Ductal
  • Pancreatic Neoplasms
  • Quality of Life

abstract

  • The treatment of choice of metastatic PADC is systemic chemotherapy. In the last decade, there have been significant advances in this area. New combination poli-chemotherapy schemes have shown a significant increase in overall survival and progression-free survival without impairing quality of life. In addition, the value of second-line chemotherapy treatment has consolidated and a new concept called "therapeutic sequencing" has also emerged. The aim of this article is to review the different therapeutic options in metastatic PDAC based on patient's characteristics.

publication date

  • December 2017

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s12094-017-1690-6

PubMed ID

  • 28623515

Additional Document Info

start page

  • 1423

end page

  • 1429

volume

  • 19

number

  • 12